EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Amelogenin Null Mice Develop Osteoarthritis, While Its Application Mitigates Disease Phenotypes in a Rat Model

Omer Helwa-Shalom iD, Yarden Kahlon-Suki iD, Shany Ivon Markowitz iD, Koby Goren iD, Dekel Shilo iD, Shira Schoonmaker iD, Chen Yochanan iD, Yechiel N Gellman iD, Shaul Beyth iD, Dan Deutsch iD, Anat Blumenfeld iD, Hani Nevo iD und 1 weitere

The FASEB Journal · 2025

DOI: 10.1096/fj.202500827r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Omer Helwa-Shalom und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Inter-Faculty Biotechnology Program, The Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Amelogenin, Osteoarthritis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Israel Science Foundation (ISF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous studies have demonstrated that recombinant human amelogenin protein (rHAM + ) promotes healing of injured articular cartilage, subchondral bone, and skeletal ligaments. Therefore, we speculated that amelogenin may play a role in osteoarthritis (OA) development. Aged amelogenin‐null and wild‐type mice underwent micro‐computed tomography (micro‐CT) and histological analyses to assess OA‐related changes. Additionally, OA was induced in rat knees via destabilization of the medial meniscus, followed by treatment with 0.5 mg/mL rHAM + dissolved in propylene glycol alginate (PGA) or PGA alone. Magnetic resonance imaging (MRI) and histological analyses were performed. Twenty‐three‐month‐old amelogenin‐null mice exhibited severe OA features, including cartilage loss, joint space narrowing, and osteophyte formation, whereas wild‐type mice showed only mild, age‐related changes. OA pathology was evident in 12‐month‐old amelogenin‐null mice, by increased matrix metalloproteinase‐13 (MMP‐13) and decreased type II collagen expression. In osteoarthritic rats, MRI analyses demonstrated that treatment with rHAM + delayed disease progression and improved OA phenotypes. Twenty‐four weeks posttreatment, the levels of type II collagen increased, while MMP‐13 and type X collagen decreased. MMP‐13 reduction was detected as early as 2 weeks posttreatment, contributing to cartilage preservation. Furthermore, similar to the known effect of rHAM + in acute injuries, recruitment of CD105‐positive mesenchymal stem cells to the cartilage was detected 5 days posttreatment. Lack of amelogenin led to the development of osteoarthritic phenotypes, whereas in the induced osteoarthritis model, a single application of amelogenin inhibited joint deterioration and partially healed osteoarthritic damage compared with the control. These findings highlight the potential of amelogenin as a disease‐modifying agent for OA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmelogeninOsteoarthritisAnimalsRatsMiceMice, KnockoutDisease Models, AnimalMaleCartilage, ArticularPhenotypeRats, Sprague-DawleyX-Ray MicrotomographyMatrix Metalloproteinase 13Mice, Inbred C57BL

Stichwörter der Autor:innen

amelogeninamelogenin‐null micecartilagecollagendestabilization of medial meniscus (DMM)matrix metalloproteinase 13osteoarthritis

Substanzen

AmelogeninMatrix Metalloproteinase 13

Autor:innen und Institutionen

  • The Inter-Faculty Biotechnology Program, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • General Surgery Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Department of Oral and Maxillofacial Surgery, Rambam Medical Care Center, Haifa, Israel.
  • Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Orthopedic Surgery Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

ORCID-Profile: Omer Helwa-Shalom, Yarden Kahlon-Suki, Shany Ivon Markowitz, Koby Goren, Dekel Shilo, Shira Schoonmaker, Chen Yochanan, Yechiel N Gellman, Shaul Beyth, Dan Deutsch, Anat Blumenfeld, Hani Nevo, Amir Haze

Förderung

  • Israel Science Foundation (ISF)

Zitieren

APA

Helwa-Shalom, O., Kahlon-Suki, Y., Markowitz, S. I., Goren, K., Shilo, D., Schoonmaker, S., Yochanan, C., Gellman, Y. N., Beyth, S., Deutsch, D., Blumenfeld, A., Nevo, H., & Haze, A. (2025). Amelogenin Null Mice Develop Osteoarthritis, While Its Application Mitigates Disease Phenotypes in a Rat Model. The FASEB Journal. https://doi.org/10.1096/fj.202500827r

Vancouver

Helwa-Shalom O, Kahlon-Suki Y, Markowitz SI, Goren K, Shilo D, Schoonmaker S, et al. Amelogenin Null Mice Develop Osteoarthritis, While Its Application Mitigates Disease Phenotypes in a Rat Model. The FASEB Journal. 2025. doi:10.1096/fj.202500827r

BibTeX
@article{HelwaShalom2025,
  author = {Helwa-Shalom, Omer and Kahlon-Suki, Yarden and Markowitz, Shany Ivon and Goren, Koby and Shilo, Dekel and Schoonmaker, Shira and Yochanan, Chen and Gellman, Yechiel N and Beyth, Shaul and Deutsch, Dan and Blumenfeld, Anat and Nevo, Hani and Haze, Amir},
  title = {Amelogenin Null Mice Develop Osteoarthritis, While Its Application Mitigates Disease Phenotypes in a Rat Model},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202500827r}
}
Kostenlos starten →